Thanks for posting. There are some posters here (like you) who are well researched and the more knowledge you impart the higher quality these threads will be for everyone.
I’d add that GW Pharma hit a US$3 billion MC prior to generating one dollar of revenue from Epidiolex. Then revenue kicked off, scaled up quickly and Jazz acquired them for US$7.4 billion. This is not an isolated example in biotech stocks and it’s why we’re invested.
I think we all appreciate the clinical risk/reward but the probability of one indication becoming a drug is statistically higher with 5 independent trials and soon to be six. And OSA does appear to be advancing in the right direction.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-11239
-
-
- There are more pages in this discussion • 8,658 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online